Isotechnika Announces Agreement From the FDA on a Special Protocol Assessment ... MarketWatch (press release) Both phase 3 trials will aim to demonstrate non-inferiority in an efficacy endpoint, primarily driven by biopsy proven acute rejection, or BPAR, compared to tacrolimus. A key secondary endpoint will be the incidence of New Onset Diabetes After ... |
